W
WAVEMAN · COMPANY
AGIO · Agios Pharmaceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

AGIO

AGIOS PHARMACEUTICALS, INC.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001439222
CONGRESS · 1FORM 144 · 2☆ WATCH
INSIDER NET · 180D
-$2.3M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
1
FUNDS ADDED · QTR
136
13F, latest reported quarter
REVENUE GROWTH
+48.0%
XBRL, annual
NET MARGIN
-764.0%
CONVERSIONS · 180D
18
codes C/M, not in net · $0 priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$2.3M over 180 days
-$1.1M over 90 days
below 70% of Pharma & Biotech
CONGRESS
1 member bought in the last year
the lowest in Pharma & Biotech
FUNDS
136 funds added or opened last quarter
more than 76% of Pharma & Biotech
REVENUE
+48.0% year over year
more than 78% of Pharma & Biotech
MARGIN
-764.0% net margin
below 86% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
11.5% of shares outstanding short · 5.1 days to cover · settled 2026-07-31
more than 81% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$2.3M across 6 people in 180 days.
136 funds added or opened positions in the latest 13F quarter, of 239 holders.
1 member of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -15.7%
-15.7%12M
-43%-23%-4%+16%2025-092025-102025-122026-032026-052026-072026-09 2026-08-04 · Gheuens Sarah sold $914.4K2026-04-02 · Goff Brian sold $432.9K2025-12-30 · Goff Brian sold $337.9K2025-09-05 · Washburn Theodore James Jr. sold $315.1K2026-03-02 · Goff Brian sold $239.4K2026-04-02 · Goff Brian sold $228.9K2026-03-02 · Goff Brian sold $171.4K2025-12-30 · Goff Brian sold $168.8K2026-03-03 · Washburn Theodore James Jr. sold $152.3K2026-07-01 · Gheuens Sarah sold $150.5K2025-10-27 · Gheuens Sarah sold $145.0K2025-09-26 · Jones Cecilia sold $134.2K2026-04-02 · Burns James William sold $113.8K2026-04-02 · Milanova Tsveta sold $113.2K2026-03-02 · Goff Brian sold $112.1K2026-04-02 · Jones Cecilia sold $109.0K2025-11-11 · Gheuens Sarah sold $107.4K2026-04-02 · Viswanadhan Krishnan sold $102.7K2026-04-02 · Gheuens Sarah sold $102.0K2026-03-05 · Viswanadhan Krishnan sold $82.3K2025-12-30 · Burns James William sold $79.4K2025-12-30 · Gheuens Sarah sold $79.4K2025-12-30 · Milanova Tsveta sold $79.4K2025-12-30 · Jones Cecilia sold $79.4K2026-01-05 · Milanova Tsveta sold $77.6K2026-03-02 · Burns James William sold $48.7K2026-03-02 · Gheuens Sarah sold $48.7K2026-03-02 · Jones Cecilia sold $48.7K2026-03-02 · Milanova Tsveta sold $48.7K2026-03-02 · Jones Cecilia sold $45.6K2026-03-02 · Burns James William sold $34.4K2026-03-02 · Gheuens Sarah sold $34.4K2026-03-02 · Jones Cecilia sold $34.4K2026-03-02 · Milanova Tsveta sold $34.4K2026-03-02 · Burns James William sold $33.7K2026-03-02 · Washburn Theodore James Jr. sold $23.1K2026-03-02 · Washburn Theodore James Jr. sold $21.1K2026-03-02 · Washburn Theodore James Jr. sold $20.2K2026-03-02 · Jones Cecilia sold $17.2K2025-11-12 · Scadden David sold $8.8K2025-10-30 · Gheuens Sarah sold $8.8K2025-10-08 · Scadden David sold $8.2K2026-08-04 · SARAH GHEUENS filed to sell $914.3K2026-07-01 · Gheuens Sarah filed to sell $150.5K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $2.3M sold by insiders over 180 days, 136 funds added last quarter, 1 Congress member(s) bought in 12 months, $1.1M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, AGIOS PHARMACEUTICALS, INC. insiders sold a net $2.3M of stock across 146 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Gheuens Sarah
Chief Medical Officer
SELL
2026-08-04
30,000.0
$914.4K
Gheuens Sarah
Chief Medical Officer
SELL
2026-07-01
4,007.0
$150.5K
Burns James William
Chief Legal Officer
SELL
2026-04-02
3,280.0
$113.8K
Gheuens Sarah
Chief Medical Officer
SELL
2026-04-02
2,940.0
$102.0K
Jones Cecilia
Chief Financial Officer
SELL
2026-04-02
3,141.0
$109.0K
146 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 141 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Lynx1 Capital Management LP
6,817,874.0 sh
$253.0M
BlackRock, Inc.
6,455,997.0 sh
$239.6M
FARALLON CAPITAL MANAGEMENT, L.L.C.
5,917,400.0 sh
$219.6M
STATE STREET CORP
3,533,633.0 sh
$131.1M
D. E. Shaw & Co., Inc.
3,107,005.0 sh
$115.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
SARAH GHEUENS
FILED 2026-08-04
$914.3K
Gheuens Sarah
FILED 2026-07-01
$150.5K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Virtus Biotech Etf
$971.7K POSITION · AS OF 2026-04-30
1.6%
AMG GW&K Small Cap Value Fund
$2.5M POSITION · AS OF 2026-03-31
1.2%
AlphaCentric Life Sciences and Healthcare Fund
$472.6K POSITION · AS OF 2026-03-31
1.2%
ALPS Medical Breakthroughs ETF
$1.6M POSITION · AS OF 2026-02-28
1.1%
AMG GW&K Small/Mid Cap Growth Fund
$426.7K POSITION · AS OF 2026-04-30
1.0%
AMG GW&K Small Cap Core Fund
$6.7M POSITION · AS OF 2026-03-31
1.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 25 registered trials, 15 still enrolling or running — a status change here is dated weeks before the press release
7
Phase 1
2 ACTIVE
5
Phase 2
3 ACTIVE
8
Phase 3
7 ACTIVE
1
Phase 4
1 ACTIVE
3
Not applicable
1 ACTIVE
1
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$54.0M$36.5M$26.8M$14.2M
OPERATING INCOME$-472.1M$-425.7M$-391.5M$-389.0M
NET INCOME$-413.0M$674.0M$-352.0M$-232.0M
EPS (DILUTED)-7.1211.64-6.33-4.23
OPERATING CASH FLOW$-373.0M$-389.8M$-296.1M$-309.5M
CASH$89.1M$76.2M$88.2M$139.3M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →